Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ThromboGenics
Biotech
Oxurion fails phase 2 eye disease trial, plans bankruptcy filing
The last program standing in what was once a three-front attack on eye diseases failed, prompting Oxurion to start preparing to file for bankruptcy.
Nick Paul Taylor
Nov 20, 2023 8:30am
Oxurion stops investing in cancer spinout, reduces head count
Jun 25, 2021 7:45am
Chutes & Ladders—GlaxoSmithKline CSO Vallance out, Hal Barron in
Nov 10, 2017 8:14am
EuroBiotech: More Articles of Note
Jul 13, 2017 6:15am
